Skip to content

Study · Case report or series · n = 1 · 2014

1 result

Clinical management of youth with gender dysphoria in Vancouver.

Khatchadourian K, Amed S, Metzger DL

The Journal of pediatrics5 Dec 2013Cited by 112 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    One youth with gender dysphoria tolerated triptorelin after a switch from leuprolide acetate because of sterile abscesses.

    In plain wordsOne youth tolerated triptorelin after leuprolide caused sterile abscesses.

    Outcome
    Not applicableTolerability after switch
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    One FtM patient developed sterile abscesses with leuprolide acetate; he was switched to triptorelin and tolerated this well.
    1 context sentence
    Summary · context
    A retrospective chart review of 84 youth with a diagnosis of gender dysphoria seen at BC Children's Hospital from 1998-2011.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.